Intrexon | XON - Заемный капитал





Заемный капитал Изменить Дата
Agenus USD 169.66M 146.06M 2025-12
Alaunos Therapeutics USD 4.47M 5.85M 2022-06
Amgen USD 51.89B 1.88B 2026-03
Arrowhead Research USD 538.1M 323.22M 2025-12
AstraZeneca USD 25.96B 177M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Gilead Sciences USD 22.13B 6M 2025-12
GlaxoSmithKline GBP 14.01B 696M 2026-03
Heron Therapeutics USD 140.64M 975K 2025-12
Incyte USD 29.41M 785K 2026-03
Intrexon USD 0 198.67M 2024-06
Karyopharm Therapeutics USD 278.22M 278.22M 2025-12
Ligand Pharmaceuticals USD 445.49M 445.44M 2025-09
MacroGenics USD 70M 256K 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 46.67B 77M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Rigel Pharmaceuticals USD 0 0 2024-09
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Thermo Fisher Scientific USD 40.07B 4.22B 2026-03
Veracyte USD 0 0 2025-03
Xencor USD 76.48M 11.29M 2025-12